Dynamic Quantitative T1 Mapping in Orthotopic Brain Tumor Xenografts  by Herrmann, Kelsey et al.
www.transonc.com
Trans la t iona l Onco logy Volume 9 Number 2 April 2016 pp. 147–154 147Dynamic Quantitative T1
Mapping in Orthotopic Brain
Tumor Xenografts1Kelsey Herrmann*, Bernadette O. Erokwu†,
Mette L. Johansen‡, James P. Basilion†, §, ¶,
Vikas Gulani†, §,#, Mark A. Griswold†, §,
Chris A. Flask†, §,** and Susann M. Brady-Kalnay*,‡
*Department of Neurosciences, School of Medicine, Case
Western Reserve University, Cleveland, OH, 44106, USA;
†Department of Radiology, School of Medicine, Case
Western Reserve University, Cleveland, OH, USA;
‡Department of, Molecular Biology and Microbiology,
School of Medicine, Case Western Reserve University,
Cleveland, OH, 44106-4960, USA; §Department of
Biomedical Engineering, Case Western Reserve University,
Cleveland, OH, USA; ¶NFCR Center for Molecular Imaging at
CWRU; #Department of Urology, Case Western Reserve
University, Cleveland, OH, USA; **Department of Pediatrics,
Case Western Reserve University, Cleveland, OH, USAAbstract
Human brain tumors such as glioblastomas are typically detected using conventional, nonquantitative magnetic
resonance imaging (MRI) techniques, such as T2-weighted and contrast enhanced T1-weighted MRI. In this
manuscript, we tested whether dynamic quantitative T1 mapping by MRI can localize orthotopic glioma tumors in
an objective manner. Quantitative T1 mapping was performed by MRI over multiple time points using the
conventional contrast agent Optimark. We compared signal differences to determine the gadolinium
concentration in tissues over time. The T1 parametric maps made it easy to identify the regions of contrast
enhancement and thus tumor location. Doubling the typical human dose of contrast agent resulted in a clearer
demarcation of these tumors. Therefore, T1 mapping of brain tumors is gadolinium dose dependent and improves
detection of tumors by MRI. The use of T1 maps provides a quantitative means to evaluate tumor detection by
gadolinium-based contrast agents over time. This dynamic quantitative T1 mapping technique will also enable
future quantitative evaluation of various targeted MRI contrast agents.
Translational Oncology (2016) 9, 147–154Address all correspondence to: Susann M. Brady-Kalnay, Department of, Molecular
Biology and Microbiology, School of Medicine, Case Western Reserve University,
Cleveland, OH, 44106-4960, USA.
E-mail: susann.brady-kalnay@case.edu
1This study was funded by a grant from theNational Cancer Institute of theNational Institutes
ofHealth (R01CA179956). The Visual SciencesHistology Core Facility is supported by a core
grant from the National Eye Institute of the National Institutes of Health (EY11373).
Received 13 October 2015; Revised 16 February 2016; Accepted 24 February 2016
© 2016 Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1936-5233/16
http://dx.doi.org/10.1016/j.tranon.2016.02.004Introduction
Gliomas are the most common primary malignant brain tumor
in adults [1]. High-grade glioma, or glioblastoma (GBM), is one
of the most aggressive and lethal types of brain cancer. The
standard treatment for GBM involves maximal safe surgical
resection of the tumor mass [2]. More complete resection has
been linked to improved survival [3]. Surgery is followed by radiation
and adjuvant temozolomide chemotherapy, but despite this three-
pronged treatment strategy, the median survival of a GBM patient
is only 15 months [4]. One of the key features of GBMs is
their dispersive, infiltrative nature, which makes visualization of the
tumor difficult [5].
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surgical planning, and evaluation of treatment efficacy of GBM
patients. Conventional MRI for brain tumor diagnosis employs
T1-weighted, contrast-enhanced T1-weighted, and T2-weighted
sequences, but these images are qualitative and require subjective
interpretation. There is difficulty locating these tumors on MRI both
before and after surgery due to their dispersal. These conventional MRI
images generally show the location of the main tumor mass but suffer
from poor tumor-to-background contrast resulting in imprecise
location of the full extent of the tumor and its borders. MRI contrast
agents, i.e., gadolinium chelates, improve the visibility of structures and
pathologies, thereby increasing tumor-to-background contrast. Gadoli-
nium-based MRI contrast agents provide contrast enhancement due to
the nonspecific leakage of gadolinium out of abnormal vasculature into
the extracellular space in the tumor [6]. Gadolinium-basedMRI contrast
agents shorten the T1 relaxation time and alter the T1 values differently
in different tissues. This decrease in T1 relaxation time is directly
proportional to the tissue concentration of contrast agent. Using the
absolute T1 values in the brain before and after intravenous injection of
contrast agent, a measurement of contrast agent concentration per voxel
of the tumor can be calculated. T2-weighted/fluid-attenuated inver-
sion-recovery (FLAIR) sequences have the ability to distinguish edema
from tumor [6] and may also be useful in evaluating nonenhancing
tumor regions [7]. Yet, the results of these various MRI sequences are
highly variable in the clinic and are qualitative in nature [6].
T1 relaxation timemapping yields absolute T1 relaxation time values,
thereby offering an objective quantitative, longitudinal evaluation of
1) tumor/tissue concentration of the MRI contrast agent at all imaging
time points, 2) increased injected contrast agent, 3) invasive and
noninvasive gliomas, and 4) therapeutic efficacy. The dynamic T1
mapping method enables quantitative assessments of gadolinium
concentration in tissues and allows for the assessment of maximum
contrast agent accumulation and clearance over time as opposed to
subjective evaluation of changes in contrast enhancement on radiologic
images. Importantly, through the use of T1 maps, radiologists will not
have to rely on qualitative information to determine tumor location but
will be able to quantitatively locate a tumor and its borders.
Measurable human disease in radiographic images of GBM is
defined as a bidimensionally contrast-enhancing lesion with clearly
defined margins by computed tomography or MRI scan, with 2
perpendicular diameters of at least 10 mm, visible on 2 or more axial
slices that are preferably, at most, 5 mm apart with 0-mm skip [7].
We developed a series of xenograft models to study brain tumors in an
orthotopic setting [8]. Depending upon the cell line and number of
days postimplantation that the MRI was performed, these models
have tumors that are of variable sizes of 1 to 4 mm. In these xenograft
models, it is difficult to reliably detect any of these tumors with
qualitative MRI as the various tumor models exhibit differential
endogenous MRI properties (i.e., T1, T2, etc.) and contrast uptake,
thereby limiting our ability to reliably study these glioma models in
detail. Due to its quantitative nature, we hypothesize that dynamic
mapping of T1 relaxation time during contrast agent injection can be
used to objectively locate these xenograft brain tumors and to track
gadolinium-based contrast uptake over time.
To test this hypothesis, we employed a T1 mapping sequence and
generated quantitative T1 and gadolinium concentration maps using
the gadolinium-based contrast agent Optimark (gadoversetamide) to
enhance mouse orthotopic xenografts of human Gli36Δ5 glioma
cells. This orthotopic glioma model was generated by transplantingGli36Δ5 cells that constitutively overexpress the vIII mutant forms of
the EGFR gene, a mutation frequently found in GBM tumors [9],
into the brains of athymic mice [8]. Using human Gli36Δ5 cells
implanted in the mouse brain for 7 to 10 days, we created tumors that
present as a highly vascularized mass of ~ 1.5 × 2 × 3.5 mm (or 10.5
mm3) in size. We observed the reliable detection of these orthotopic
mouse brain tumors using quantitative T1 mapping techniques and a
conventional clinical contrast agent at multiple dose levels on a 9.4-T
preclinical MR scanner. To evaluate the quantitative nature of the T1
mapping technique, we compared tumor enhancement using two
doses of Optimark. Doubling the dose of contrast agent in the mouse
system resulted in a greater decrease in T1 relaxation time, allowing
for clear demarcation of tumors in the maps.
These data demonstrate that T1 mapping of brain tumors is
feasible, is gadolinium dose dependent, and provides reliable
detection of tumors. By doubling the dose of the MRI contrast
agent, we found that the tumor is further enhanced, facilitating the
ability to detect smaller orthotopic mouse brain tumors. Evaluation of
the T1 relaxation time maps as well as estimated tumor gadolinium
concentrations calculated across animals over time demonstrates that
these values are reproducible between different animals. Therefore,
we conclude that T1 maps and gadolinium concentration maps
provide a quantifiable and reproducible means of visualizing
intracranial tumor enhancement over time. We suggest that the use
of T1 mapping provides a quantitative means to evaluate tumors in
the clinic to ultimately track tumor response to therapy.
Material and Methods
Orthotopic Xenograft Intracranial Tumors
NIH athymic nude female mice (NCr-nu/+, NCr-nu/nu) were
bred in the Athymic Animal Core Facility and housed in the Case
Center for Imaging Research at Case Western Reserve University
according to institutional policies. The Institutional Animal Care and
Use Committee approved all animal protocols.
The Gli36Δ5 cells [10] were obtained from E.A. Chiocca and
authenticated by Research Animal Diagnostic Laboratory at the
University of Missouri (Columbia, MO) for interspecies and
mycoplasma contamination by PCR analysis.
Gli36Δ5 cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum. Gli36Δ5 cells were
infected with lentivirus to express green fluorescent protein [11] 48
hours prior to harvesting. Cells were harvested for intracranial
implantation by trypsinization and concentrated to 1 × 105 cells per
microliter of PBS. Mice 6 to 7 weeks of age were anesthetized by
intraperitoneal administration of 50mg/kg ketamine/xylazine and fitted
into a stereotaxic rodent frame (David Kopf Instruments, Tujunga,
CA). A small incision was made to expose the bregma suture. A small
(0.7mm) burr hole was made 0.7 mm anterior and 2.0 mm lateral from
bregma. Cells were slowly deposited at a rate of 1 μl/min for a total of
200,000 cells into the right striatum at a depth of −3mm from the dura
using a 10-μl syringe (26-gauge needle; Hamilton Co, Reno, NV). The
needle was slowly withdrawn, and the incision was closed with sutures.
Mice were imaged as described below and then sacrificed 10 days after
tumor implant. Brain tissue was collected for histological processing.
Magnetic Resonance Imaging
The MRI studies were performed using a Bruker Biospec 9.4-T
preclinical MRI scanner (Bruker Corp., Billerica, MA) with a 35 mm
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brain tumors were scanned 7 to 10 days after tumor implantation
using a clinically approved MRI contrast agent, Optimark (Mal-
linckrodt Pharmaceuticals, St. Louis, MO, FW 661.77).
Dynamic T1 Relaxation Time Mapping MRI Acquisition
Tumor-bearing mice were catheterized prior to the imaging study.
In brief, polyurethane tubing (0.014″ ID × 0.033″ OD) (SAI
Infusion Technologies, Lake Villa, IL) was connected to a 1-ml
syringe and preloaded with the appropriate amount of Optimark
diluted in PBS or saline. After mice were anesthetized with a 2%
isoflurane-oxygen mixture in an induction chamber, tail veins
were catheterized using a 26-gauge veterinary catheter and connected
to the preloaded tubing described above. The animals were
moved into the magnet in the prone position and kept under
inhalation anesthesia with 1.5% isoflurane-oxygen via a nose cone. A
respiratory sensor connected to a monitoring system (SA Instruments,
Stony Brook, NY) was placed on the back of the animal to monitor
rate and depth of respiration. Body temperature was maintained at
35 ± 2°C by blowing warm air into the magnet through a feedback
control system.
T2-weighted images were first obtained for each mouse using a rapid
acquisition with relaxation enhancement sequence [repetition time
(TR)/echo time (TE) = 5000milliseconds/40milliseconds, resolution =
0.078 × 0.078 × 0.5 mm, field of view = 20 × 20 mm, and three signal
averages] to select the imaging slice for the dynamic T1 relaxation time
acquisition [12]. The quantitative T1 data were acquired using a
snapshot gradient recalled echo (GRE) sequence with inversion
recovery preparation described previously [10 inversion times (519,
1031, 1543, 2055, 2567, 3079, 3591, 4103, 4615, and 5127
milliseconds), GRE imaging readout TR/TE = 4.0 milliseconds/1.9
milliseconds, flip angle = 10°, resolution = 0.156 × 0.156 × 1 mm, field
of view = 20 × 20 mm, and 10 signal averages] [13,14]. The total
acquisition for each T1 mapping scan was 2.5 minutes.
Three T1 mapping baseline images were acquired before injecting
Optimark at a dose of 0.1 mmol Gd/kg. T1maps were acquired every 5
minutes, alternating with T1-weighted scans, for a total of 60 minutes.
T1 Mapping
The T1 mapping data were then acquired using a slightly different
sequence than that described above [10 inversion times (263, 775,
1287, 1799, 2311, 2823, 3335, 3847, 4359, and 4871 milliseconds),
GRE imaging readout TR/TE = 4.0 milliseconds/1.3 milliseconds, flip
angle = 10°, resolution = 0.234 × 0.234with a slice thickness of 1.5mm,
field of view = 30 × 30 mm, 10 signal averages for a total scan time of
2.5 minutes]. As described above, Optimark at 0.1- or 0.2-mmol/kg
was administered after acquiring three baseline scans (n = 9 for
Optimark at 0.1-mmol/kg, n = 7 for Optimark at 0.2-mmol/kg).
Generation of T1 Relaxation and Gadolinium Concentration Maps
The MRI data were imported into MATLAB, and the quantitative
T1 relaxation maps were generated from the T1 mapping acquisition
using previously described methods based on monoexponential
models [14]. Dynamic maps of gadolinium concentration maps










¼ r1  Gd½ where T1 is the measured T1, r1 is the relaxivity value measured at
37°C on the Bruker Biospec 9.4-T scanner, and [Gd] is the
gadolinium concentration. Median filtering was performed in
MATLAB on the normalized T1 relaxation and gadolinium
concentration maps to remove salt and pepper noise.
Evaluation of Dynamic T1 Mapping Values and Gadolinium
Concentration in Orthotopic Xenograft Mouse Glioma Models
Once the maps were generated, the mean T1 relaxation and
gadolinium concentration values were determined by performing a
region of interest (ROI) analysis. For each mouse, an ROI was drawn
around the tumor using the parametric map generated at 5 minutes
postinjection when tumor enhancement was greatest. The same ROI
was then applied to all of the T1 maps, the average value in the ROI
was calculated for each time point, and normalized T1 values were
obtained by dividing each T1 value by the mean baseline T1 value.
Gadolinium concentrations were calculated using measured T1 values
and the relaxivity of Optimark.
Histology
Brain tissue was harvested and fixed in 4% formalin for
approximately 72 hours. Tissues were paraffin embedded and
sectioned at 7 to 10 μm in thickness. Hematoxylin and eosin
(H&E) staining was performed to visualize the main tumor mass.
Images were captured with a 20× objective using a Leica SCN400
microscope. Full tissue images were viewed using the Leica SCN400
Image Viewer version 2.2 software. Images were viewed at a 20×
zoom using the Aperio ImageScope version 12.1 software.
Results
Tumor Preparation and Validation
To detect small mouse orthotopic brain tumors, we performed a
contrast-enhanced T1 mapping study to directly evaluate tumor
enhancement using a conventional contrast agent. High-resolution
T2-weighted MR images were acquired of Gli36Δ5 glioma tumors in
athymic mice 7 to 10 days postimplantation. Using T2-weighted
images, we were able to localize the tumors and identify the largest
tumor cross section on MRI. This cross section then served as the
reference for the position of the T1 slice (Figure 1A). Despite our a
priori knowledge of the implantation site of the noninvasive Gli36Δ5
tumors [8], tumors of this size were not routinely evident in the
T1-weighted images (Figures 1 and 2).
Evaluation of Orthotopic TumorUsingQuantitative T1Mapping
We hypothesized that a contrast-enhanced quantitative T1
mapping technique would allow the generation of T1 parametric
maps to enable visualization of contrast enhancement across the entire
brain slice and thus allow us to detect these tumors. Quantitative T1
mapping is performed on a single MR slice. As a reference for the
dimensions shown in the figures, the tumor size in this study was
approximately 1.5 × 2 × 3.5 mm. The MR slice thickness is 1 to 1.5
mm. Therefore, the majority of the tumor is in 1 to 2 MR slices out of
approximately 350 histological sections (7 μm thick) in 1 tumor.
T1 mapping sequences were acquired before and after administra-
tion of Optimark. Injection of the gadolinium-based contrast agent
Optimark resulted in decreased T1 relaxation times, as expected
(Figure 1). T1 mapping is a quantitative MRI method that yields
absolute T1 relaxation values as opposed to the relative signal
intensity values in conventional T1-weighted images. Using the
Figure 1. Evaluation of tumor enhancement using quantitative T1 mapping. (A) Representative bright-field images of athymic mice
bearing Gli36Δ5 glioma tumors. T2-weighted high-resolution images show the tumor mass and are co-registered with their
corresponding T1-weighted images and normalized T1 maps. An H&E-stained histological section shows tumor size, shape, and
location. Scale bar represents 1 mm. (B) T1-weighted, snapshot GRE acquired, images of an orthotopic Gli36Δ5 glioma tumor at baseline
(before injection of 0.1-mmol/kg Optimark), 5 minutes following the injection (peak contrast), and 22.5 minutes postinjection (contrast
agent clearance). (C) Normalized T1 maps of the tumor-bearing brains are overlaid onto T1-weighted images at baseline and at 5 and
22.5 minutes postinjection. The color-coded scale bar indicates normalized T1 map values with dark blue representing zero and red
representing 1.2; the marks are in 0.2 increments. (D) Gadolinium concentration maps of the tumor-bearing brains are overlaid onto
T1-weighted images at baseline and at 5 and 22.5 minutes postinjection. The color-coded scale bar indicates gadolinium concentration in
mM with dark blue representing zero and red representing 0.06; the marks are in 0.01 increments.
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ric maps were generated before and after contrast administration for
the orthotopic brain tumor xenografts (Figure 1C). For clarity and to
enable intermouse comparisons, the heat maps shown are normalized
to the mean precontrast T1 value of whole brain. As shown in
Figure 1C, the tumor is visible in these maps (represented by cyan;tumor average = 0.820) at 5 minutes and recovers towards baseline at
20 minutes after Optimark administration (tumor average = 0.902).
Tissue concentration of gadolinium is proportional to the measured
T1 mapping values and enables the generation of quantitative
gadolinium concentration maps. The tumor is visible in the
gadolinium concentration map (represented by yellow, orange, and
Figure 2. The conventional imaging agent Optimark results in tumor
enhancement of orthotopic glioma tumors in mice at 0.1- and
0.2-mmol/kg. Representative bright-field images of athymic mice
bearing Gli36Δ5 glioma tumors that received 0.1- or 0.2-mmol/kg
Optimark. T2-weightedhigh-resolution imagesshow the tumormass
and are co-registered with their corresponding T1-weighted images
below and quantitativemaps in Figures 3 and 5. T1-weighted images
of orthotopic Gli36Δ5 glioma tumors at baseline (before injection of
contrast agents) and at time of maximum contrast (5 minutes)
following intravenous administration are shown.
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administration (Figure 1D). The 7 μm histological section shown in
Figure 1A corroborates the general size and shape of the tumor
observed. The normalized T1 and gadolinium concentration maps 5
minutes postcontrast represent the combined signal from an MR slice
of 1.5 mm.
Quantitative, Contrast-Enhanced T1 Mapping
Quantitative T1 mapping and the generation of parametric maps
enabled the detection of brain tumors in our mouse model of glioma
(Figure 1). To evaluate the objective nature of T1 mapping methods,we hypothesized that administration of 0.1- and 0.2-mmol/kg
Optimark would decrease T1 values in a dose-dependent manner.
Representative brightfield, fluorescence, and MR images are shown in
Figure 2. The T2-weighted scans do not clearly show the tumors, but
an anatomical abnormality is apparent (Figure 2). The T1-weighted
snapshot GRE images obtained with the T1 mapping sequence
are shown at baseline and peak tumor enhancement postcontrast
(5 minutes). Tumor masses were not apparent in the baseline T1
mapping images. Following injection of 0.1-mmol/kg Optimark, the
tumor mass is not visible, as in Figure 1. However, there is an obvious
change in overall signal in the brain indicating that delivery of
contrast was successful (Figure 2). The 0.2-mmol/kg dose of
Optimark resulted in a similar overall signal change in the brain
along with tumor enhancement (Figure 2).
Quantitative parametric maps were generated to compare the
tumor detection ability of the 0.1-versus 0.2-mmol/kg dose of
Optimark. Representative normalized T1 maps are shown at
baseline and at 5, 15, and 30 minutes postcontrast in Figure 3 for
the 2 doses. Representative H&E-stained histological sections for
each mouse are also shown in the first row of images of Figure 3 to
verify tumor size and shape and to facilitate qualitative comparisons to
the tumor enhancement observed in the normalized T1 maps. The
0.1-mmol/kg dose of Optimark resulted in a modest decrease in
normalized T1 values (represented by yellow; tumor average = 0.798)
at 5 minutes. At 15 minutes, the normalized T1 value exhibits
recovery toward baseline due to Optimark clearance (tumor average =
0.899). By 30 minutes, there is no distinction between T1 value of
normal brain and tumor with the 0.1-mmol/kg dose (tumor average =
0.935). The 0.2-mmol/kg dose of Optimark caused a larger decrease
in normalized T1 values compared with 0.1-mmol/kg at 5 minutes
(Figure 3, 0.2-mmol/kg dose; represented by green; tumor average =
0.646). By 15 minutes, the normalized T1 values begin to recover
(tumor average = 0.690), and there is moderate enhancement
observed beyond the initial tumor borders observed at 5 minutes
(represented by yellow) that likely represents the full extent of the
tumor within the 1.5 mm slice. At 30 minutes, a weak distinction
remains between normalized T1 values of normal brain and tumor
(tumor average = 0.823).
Comparison of mean normalized T1 values in the brain tumors of
different animals demonstrates that both the 0.1- and 0.2-mmol/kg
doses of Optimark exhibited peak enhancement in the tumors at 5
minutes and then steadily returned to baseline values over the next 30
minutes (Figure 4). The 0.2-mmol/kg dose of Optimark had a larger
and statistically significant decrease (P b .00005 to P b .005
depending on the time point) in normalized T1 values at all time
points compared with the 0.1-mmol/kg dose (Figure 4).
Quantitative Mapping of Gadolinium Concentrations
Gadolinium concentration maps can also evaluate contrast
enhancement and hence tumor location using T1 mapping
sequences. Representative gadolinium concentration maps are
shown at baseline and at 5, 15, and 30 minutes postcontrast in
Figure 5 for the 0.1- and 0.2-mmol/kg doses of Optimark.
Representative H&E-stained histological sections are shown for
comparison. The 0.1-mmol/kg dose of Optimark resulted in
moderate increases in gadolinium concentration (represented by
yellow and orange; tumor average = 0.030 mM) at 5 minutes. At 15
minutes, the gadolinium concentration in the 0.1-mmol/kg dose
decreased toward baseline (represented by cyan; tumor average =
Figure 3. The 0.1-mmol/kg and 0.2-mmol/kg doses of Optimark
result in decreased normalized T1 relaxation times in orthotopic
glioma tumors, with the 0.2-mmol/kg dose resulting in a greater
decrease compared with 0.1-mmol/kg. Representative H&E-stained
histological sections show tumor size, shape, and location.
Normalized T1 maps of the tumor-bearing brains are overlaid
onto T1-weighted images at baseline and at 5, 15, and 30 minutes
postinjection. The color-coded scale bar indicates normalized T1
map values with dark blue representing the lowest and red
representing the highest normalized T1 values. Maps represent
the same slices as in Figures 2 and 5.
Figure 4.Mean normalized T1 values in the tumor before and after
intravenous administration of 0.1- or 0.2-mmol/kg Optimark in
cohorts of nu/nu athymic mice bearing orthotopic glioma tumors
(n = 9 for 0.1-mmol/kg and n = 7 for 0.2-mmol/kg Optimark). Data
plotted as means ± standard error. Mean tumor normalized T1
values at baseline and after contrast agent injection measured
every 2.5 minutes for 30 minutes. Normalized T1 values are
significantly different between the 0.1- and 0.2-mmol/kg doses
(ranges from P b .00005 to P b .006 depending on the time point).
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0.008 mM). The 0.2-mmol/kg dose of Optimark had higher
concentrations of gadolinium compared with 0.1 mmol/kg at all
time points. Peak gadolinium concentration is observed at 5 minutes
(tumor average = 0.064 mM). Similar to the normalized T1 maps,
gadolinium accumulates beyond the initial contrast area observed at 5
minutes while declining in intensity throughout the experiment.Interestingly, in the 0.2-mmol/kg dose at 30 minutes postcontrast,
the tumor borders remain distinct (tumor average = 0.025 mM) in
the gadolinium concentration maps.
Comparison of mean gadolinium concentration in different
tumors over time confirms that peak contrast agent concentration
is achieved at the 5-minute time point for both doses of Optimark
and then steadily returns to baseline (Figure 6). Consistent with the
normalized T1 values depicted in Figures 3 and 4, the 0.2-mmol/kg
dose had significantly higher levels of gadolinium concentration
compared with 0.1-mmol/kg at all time points (Figure 6).
Discussion
Novel MRI methods are being developed to detect brain tumors both
in animal models and in patients [15–18]. This study used orthotopic
animal xenograft models that allow for the control of tumor size,
location, genetics, and other parameters that permit standardization.
Despite the standardization of the model, small tumors are still
difficult to detect consistently. This is highly problematic because the
assessment of treatment response and surgical planning are based on
the accuracy of these qualitative radiographic findings.
Because clinical MRI protocols are not standardized across
institutions and are not quantitative in nature, treatment response
or failure can only be gauged when substantial changes in the tumor
are observed. Conventional nonquantitative MRI protocols are
susceptible to variations in signal intensity caused by radiofrequency
coil sensitivity issues, magnetic field inhomogeneities, and many
other sources of variation. Contrast-enhanced MRI is further
complicated by surgery, treatment, corticosteroids, and the admin-
istered dose of the MRI contrast agent [7].
To circumvent the limitations of qualitative MRI imaging, we used
a dynamic T1 mapping acquisition protocol and generated
quantitative parametric maps. This study demonstrates that mapping
of relaxation time and generation of T1 maps are highly sensitive for
tumor detection. T1 relaxation time shortening in the tumor
following administration of Optimark is evident in the color-coded
T1 maps, with peak tumor enhancement occurring at 5 minutes.
Figure 5. Gadolinium concentration maps of glioma-bearing mice
injected with 0.1-mmol/kg and 0.2-mmol/kg doses of Optimark, with
the 0.2-mmol/kg dose resulting in a greater concentration of
gadolinium compared with 0.1-mmol/kg. Representative
H&E-stained histological sections show tumor size, shape, and
location. Gadolinium concentration maps of the tumor-bearing
brains are overlaid onto T1-weighted images at baseline and at 5,
15, and30minutespostinjection. The color-coded scale bar indicates
gadolinium concentration in mM with dark blue representing the
lowest and red representing the highest gadolinium concentrations.
Maps represent the same slices as in Figures 2 and 3.
Figure 6.Mean gadolinium concentrations in the tumor before and
after intravenous administration of 0.1- or 0.2-mmol/kg Optimark in
cohorts of nu/nu athymic mice bearing orthotopic glioma tumors
(n = 9 for 0.1-mmol/kg and n = 7 for 0.2-mmol/kg Optimark).
Data plotted as means ± standard error. Mean tumor gadolinium
concentration at baseline and after contrast agent injection
measured every 2.5 minutes for 30 minutes. Gadolinium concen-
trations are significantly different between the 0.1- and 0.2-mmol/
kg doses (ranges from P b .00005 to P b .005 depending on the
time point).
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which are directly derived from the T1 maps, also show that the
highest gadolinium concentrations occur at 5 minutes. A patient
study evaluating the time course of brain lesion enhancement using
Omniscan arrived at a similar conclusion; the optimal time to observe
the effects of contrast agents in that study was 3.5 minutes
postadministration [19].Our study demonstrates that computer-generated maps are able to
determine gadolinium concentration in tissue. These maps are
sensitive enough to detect differences between 0.1- and 0.2-mmol/kg
doses of Optimark. The 0.2-mmol/kg dose of Optimark afforded
more complete tumor detection of these small glioma tumors than
the standard clinical dose of 0.1-mmol/kg. Several studies in which
administration of higher doses of contrast agent significantly
improved the enhancement of intracranial tumors clinically
[20–24] corroborate our findings. The T1 mapping sequence and
quantitative maps provide an objective quantitative method for
detection of small tumors and for the measurement of tumor
enhancement over time.
Despite having a resolution of 1 mm, the minimum size of MR
image-based detection of human brain tumors is considered to be a
bidimensionally contrast-enhancing lesion with clearly defined
margins of at least 10 mm visible in 2 or more axial slices 5 mm
apart [7]. In this manuscript, we demonstrate reliable detection of
brain tumors that are 1.5 × 2 × 3.5 mm using the quantitative T1
mapping techniques and a conventional clinical contrast agent on a
9.4-T preclinical scanner. Given that T1 mapping protocols can be
easily translated to the clinic, quantitative MRI would be especially
relevant for clinical trials to unambiguously define tumor response
and/or progression.
The mechanism of action of these widely used gadolinium-based
contrast agents is nonspecific. The coupling of quantitative T1
mapping with targeted molecular probes designed to detect
tumor-specific markers could increase tumor enhancement without
increasing the dose of gadolinium. For example, a peptide probe
designed to target PTPμ fragments generated by GBM tumors was
conjugated to a gadolinium chelate [25,26]. This probe, called SBK2,
is selectively retained in heterotopic glioma tumors compared with
scrambled and Optimark controls using T1 mapping [26]. Detection
of intracranial glioma tumors could be further improved upon by
combining disease-specific molecular contrast agents and quantitative
T1 mapping.
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By using a controlled orthotopic model, we were able to demonstrate
that T1 mapping is able to identify small tumors. We were able to
quantitatively compare multiple time points in different animals
using different contrast agent concentrations. Using T1 mapping, we
found that doubling the contrast agent concentration has a significant
impact on tumor enhancement. Given the importance of treatment
comparisons for the development and approval of therapeutics, an
objective, quantitative methodology for evaluating tumor size changes
among the same patient over time and between patients is paramount.
We demonstrate that, even with a conventional contrast agent,
T1 mapping can produce significant image quality differences.
Future studies will evaluate whether using this imaging strategy in





This study was funded by a grant from the National Cancer Institute
of the National Institutes of Health (R01 CA179956). We thank
Cathy Doller for help with histology, and the Visual Sciences
Histology Core Facility is supported by a core grant from the
National Eye Institute of the National Institutes of Health
(EY11373). The authors thank Lan Lu and Ying Gao for providing
the MATLAB code for T1 mapping analysis; Michael Howell
and Steven Cady for increasing the efficiency and throughput of the
T1 mapping analysis code; and Polly Phillips-Mason, Jason Vincent,
and Ramamurthy Gopalakrishnan for technical expertise and
experimental setup. We thank Sonya Craig for critical reading of
the manuscript.
References
[1] Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, Jemal A,
Anderson RN, Ajani UA, and Edwards BK (2011). Annual report to the nation
on the status of cancer, 1975-2007, featuring tumors of the brain and other
nervous system. J Natl Cancer Inst 103, 714–736.
[2] Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn
WC, Ligon KL, Louis DN, and Brennan C, et al (2007). Malignant astrocytic
glioma: genetics, biology, and paths to treatment. Genes Dev 21, 2683–2710.
[3] Sanai N, Polley MY, McDermott MW, Parsa AT, and Berger MS (2011). An
extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115,
3–8.
[4] Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ,
Belanger K, Brandes AA, Marosi C, and Bogdahn U, et al (2005). Radiotherapy
plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med
352, 987–996.
[5] Louis DN (2006). Molecular pathology of malignant gliomas. Annu Rev Pathol 1,
97–117.
[6] Upadhyay N and Waldman AD (2011). Conventional MRI evaluation of
gliomas. Br J Radiol 84(Spec No 2), S107–S111.
[7] Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E,
Degroot J, Wick W, Gilbert MR, and Lassman AB, et al (2010). Updatedresponse assessment criteria for high-grade gliomas: response assessment in
neuro-oncology working group. J Clin Oncol 28, 1963–1972.
[8] Burden-Gulley SM, Qutaish MQ, Sullivant KE, Lu H, Wang J, Craig SE,
Basilion JP, Wilson DL, and Brady-Kalnay SM (2011). Novel cryo-imaging of
the glioma tumor microenvironment reveals migration and dispersal pathways in
vivid three-dimensional detail. Cancer Res 71, 5932–5940.
[9] Gan HK, Cvrljevic AN, and Johns TG (2013). The epidermal growth factor
receptor variant III (EGFRvIII): where wild things are altered. FEBS J 280,
5350–5370.
[10] Tyminski E, Leroy S, Terada K, Finkelstein DM, Hyatt JL, Danks MK, Potter
PM, Saeki Y, and Chiocca EA (2005). Brain tumor oncolysis with
replication-conditional herpes simplex virus type 1 expressing the prodrug-acti-
vating genes, CYP2B1 and secreted human intestinal carboxylesterase, in
combination with cyclophosphamide and irinotecan. Cancer Res 65, 6850–6857.
[11] Tyagi M and Karn J (2007). CBF-1 promotes transcriptional silencing during the
establishment of HIV-1 latency. EMBO J 26, 4985–4995.
[12] Hennig J, Nauerth A, and Friedburg H (1986). RARE imaging: a fast imaging
method for clinical MR. Magn Reson Med 3, 823–833.
[13] Deichmann R (1969). Haase A (1992) Quantification of T1 values by
SNAPSHOT-FLASH NMR imaging. J Magn Reson 96, 608–612.
[14] Jakob PM, Hillenbrand CM,Wang T, Schultz G, Hahn D, and Haase A (2001).
Rapid quantitative lung (1)H T(1) mapping. J Magn Reson Imaging 14, 795–799.
[15] Sun Y, Schmidt NO, Schmidt K, Doshi S, Rubin JB, Mulkern RV, Carroll R,
Ziu M, Erkmen K, and Poussaint TY, et al (2004). Perfusion MRI of U87 brain
tumors in a mouse model. Magn Reson Med 51, 893–899.
[16] Coquery N, Francois O, Lemasson B, Debacker C, Farion R, Remy C, and
Barbier EL (2014). Microvascular MRI and unsupervised clustering yields
histology-resembling images in two rat models of glioma. J Cereb Blood Flow
Metab 34, 1354–1362.
[17] Sagiyama K, Mashimo T, Togao O, Vemireddy V, Hatanpaa KJ, Maher EA,
Mickey BE, Pan E, Sherry AD, and Bachoo RM, et al (2014). In vivo chemical
exchange saturation transfer imaging allows early detection of a therapeutic
response in glioblastoma. Proc Natl Acad Sci U S A 111, 4542–4547.
[18] Rose CJ, Mills SJ, O'Connor JP, Buonaccorsi GA, Roberts C, Watson Y,
Cheung S, Zhao S, Whitcher B, and Jackson A, et al (2009). Quantifying spatial
heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn Reson
Med 62, 488–499.
[19] Akeson P, Nordstrom CH, and Holtas S (1997). Time-dependency in brain
lesion enhancement with gadodiamide injection. Acta Radiol 38, 19–24.
[20] Runge VM, Kirsch JE, Burke VJ, Price AC, Nelson KL, Thomas GS, Dean BL,
and Lee C (1992). High-dose gadoteridol in MR imaging of intracranial
neoplasms. J Magn Reson Imaging 2, 9–18.
[21] Yousry I, Camelio S, Schmid UD, Horsfield MA, Wiesmann M, Bruckmann H,
and Yousry TA (2000). Visualization of cranial nerves I-XII: value of 3D CISS
and T2-weighted FSE sequences. Eur Radiol 10, 1061–1067.
[22] YuhWT, Fisher DJ, Engelken JD, Greene GM, Sato Y, Ryals TJ, Crain MR, and
Ehrhardt JC (1991). MR evaluation of CNS tumors: dose comparison study with
gadopentetate dimeglumine and gadoteridol. Radiology 180, 485–491.
[23] Yuh WT, Fisher DJ, Runge VM, Atlas SW, Harms SE, Maravilla KR, Mayr NA,
Mollman JE, and Price AC (1994). Phase III multicenter trial of high-dose
gadoteridol in MR evaluation of brain metastases. AJNR Am J Neuroradiol 15,
1037–1051.
[24] Yuh WT, Nguyen HD, Tali ET, Mayr NA, Fisher DJ, Atlas SW, Carvlin MC,
Drayer BP, Pollei SR, and Runge VM, et al (1994). Delineation of gliomas with
various doses of MR contrast material. AJNR Am J Neuroradiol 15, 983–989.
[25] Burden-Gulley SM, Zhou Z, Craig SE, Lu ZR, and Brady-Kalnay SM (2013).
Molecular Magnetic Resonance Imaging of Tumors with a PTPmu Targeted
Contrast Agent. Transl Oncol 6, 329–337.
[26] Herrmann K, Johansen M, Craig S, Vincent J, Howell M, Gao Y, Lu L, Erokwu
B, Agnes R, and Lu Z-R, et al (2015). Molecular Imaging of Tumors Using a
Quantitative T1 Mapping Technique via Magnetic Resonance Imaging.
Diagnostics 5, 318.
